We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
+5.98%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$5.26B
AUM Growth
+$740M
(+16%)
Cap. Flow
+$520M
Cap. Flow
% of AUM
9.89%
Top 10 Holdings %
Top 10 Hldgs %
40.34%
Holding
110
New
23
Increased
31
Reduced
29
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$178M |
| 2 |
AGN
Allergan plc
AGN
|
+$168M |
| 3 |
Gilead Sciences
GILD
|
+$89.7M |
| 4 |
Alibaba
BABA
|
+$67.2M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$66.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$93.9M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$77.2M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$73.7M |
| 4 |
Pfizer
PFE
|
+$50.2M |
| 5 |
Elevance Health
ELV
|
+$42.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.27% |
| 2 | Technology | 8.75% |
| 3 | Communication Services | 4% |
| 4 | Consumer Discretionary | 3.22% |
| 5 | Financials | 2.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AXNX
76
DELISTED
Axonics, Inc. Common Stock
AXNX
| $4.36M | 0.08% |
+106,328
| New | +$2.99M |
|
|
TECX
77
Tectonic Therapeutic
TECX
$536M
| $4.06M | 0.08% |
+20,786
| New | +$4.48M |
|
78
CrowdStrike
CRWD
$183B
| $3.99M | 0.08% |
+233,536
| New | +$3.97M |
|
|
ALNA
79
DELISTED
Allena Pharmaceuticals
ALNA
| $3.21M | 0.06% |
788,958
-674,250
| -46% | -$3.68M |
|
80
Tradeweb Markets
TW
$23B
| $2.94M | 0.06% |
+67,157
| New | +$2.8M |
|
81
Inspire Medical Systems
INSP
$1.47B
| $2.48M | 0.05% |
+40,963
| New | +$2.21M |
|
|
SNNA
82
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
| $2.25M | 0.04% |
2,583,712
-100,966
| -4% | -$158K |
|
|
NTGN
83
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $578K | 0.01% |
121,848
-300,548
| -71% | -$1.68M |
|
84
Agilent Technologies
A
$39.6B
| – | – |
-281,069
| Closed | -$22.6M |
|
85
Amazon
AMZN
$2.44T
| – | – |
-402,400
| Closed | -$35.8M |
|
86
Aptiv
APTV
$12.3B
| – | – |
-391,418
| Closed | -$31.1M |
|
87
Accuray
ARAY
$27.7M
| – | – |
-1,617,297
| Closed | -$7.71M |
|
|
BPMC
88
DELISTED
Blueprint Medicines
BPMC
| – | – |
-964,075
| Closed | -$77.2M |
|
89
CALL
Edwards Lifesciences
EW
$49.4B
| – | – |
-469,500
| Closed | -$29.9M |
|
90
Alphabet (Google) Class A
GOOGL
$4.12T
| – | – |
-440,980
| Closed | -$25.9M |
|
91
CALL
Humana
HUM
$43.9B
| – | – |
-393,100
| Closed | -$105M |
|
92
Lyft
LYFT
$5.87B
| – | – |
-88,182
| Closed | -$6.9M |
|
93
Live Nation Entertainment
LYV
$42.9B
| – | – |
-514,407
| Closed | -$32.7M |
|
94
NXP Semiconductors
NXPI
$60.8B
| – | – |
-360,456
| Closed | -$31.9M |
|
95
PTC Therapeutics
PTCT
$6.17B
| – | – |
-1,086,776
| Closed | -$40.9M |
|
|
SAGE
96
DELISTED
Sage Therapeutics
SAGE
| – | – |
-169,676
| Closed | -$27M |
|
97
Shopify
SHOP
$168B
| – | – |
-196,160
| Closed | -$4.05M |
|
|
UBX
98
DELISTED
Unity Biotechnology
UBX
| – | – |
-13,519
| Closed | -$1.1M |
|
99
Wave Life Sciences
WVE
$1.12B
| – | – |
-902,578
| Closed | -$35.1M |
|
100
Zai Lab
ZLAB
$2.07B
| – | – |
-157,442
| Closed | -$4.65M |
|
Similar funds
DAM
MAM
LCM
PRS
DAM
KCM
CF
MIA
PFM Health Sciences's Q2 2019 Portfolio in Review
As of Q2 2019, PFM Health Sciences held 110 positions worth $5.26B, up 16% from $4.52B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
PFM Health Sciences deployed $520M of net new capital in Q2 2019, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 2,079,388 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 55% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was UnitedHealth, an estimated $93.9M trimmed.
- PFM Health Sciences's largest Q2 2019 buy was BioMarin Pharmaceuticals: 2,079,388 shares worth $178M.
- PFM Health Sciences added most to Allergan plc in Q2 2019, an estimated $168M increase.
- PFM Health Sciences's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $93.9M.
- PFM Health Sciences fully exited Blueprint Medicines in Q2 2019, selling an estimated $77.2M.
- PFM Health Sciences's ten largest holdings make up 40% of its $5.26B portfolio in Q2 2019.
- PFM Health Sciences opened 23 new positions and closed 25 in Q2 2019.
- PFM Health Sciences's portfolio value rose 16% quarter-over-quarter to $5.26B.
Based on PFM Health Sciences's 13F filing for Q2 2019, filed 14 Aug 2019.